Completed PHASE4 INTERVENTIONAL 5-arm NCT03762824

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease (IPS-BOOSTER)

Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.

Sponsor: Region Skane

Conditions Rheumatoid Arthritis Sjögren Syndrome Spondyloarthritis Systemic Lupus Systemic Vasculitis

Interventions 13-valent pneumococcal conjugate vaccine 23-valent pneumococcal polysaccharide vaccine

Updated 7 times since 2019 Last updated: Mar 28, 2023 Started: Jun 14, 2016 Primary completion: Sep 3, 2018 Completion: Dec 21, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03762824, this PHASE4 trial focuses on Rheumatoid Arthritis and Sjögren Syndrome and remains completed. Sponsored by Region Skane, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2023 — Jul 2024 [monthly]

Completed PHASE4
Mar 2021 — Apr 2023 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE4

▶ Show 2 earlier versions

Feb 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE4
Jan 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE4

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Region Skane

Data source: Region Skane

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.